// App-Quantinova.ai

2342 : NKG2A immune checkpoint blockade enhances the anti-tumor efficacy of PD1/PD-L1 inhibitors in a preclinical model

Researchers

Presenter

  • Caroline Sola

Principal Investigators

  • Thomas Arnoux

  • Fabien Chanuc

  • Nicolas Fuseri

  • Benjamin Rossi

  • Laurent Gauthier

  • Corinne Leget

  • Cecile Bonnafous

  • Nicolai Wagtmann

  • Yannis Morel

  • Pascale Andre

Medical Centers

  • INNATE PHARMA, Marseille, France

Locations

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Hematological malignancies

  • Solid malignancies

Biomarkers

  • Programmed death-ligand 1

  • Cluster of differentiation 8A

Drug/Treatment

  • Monalizumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved